Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (88)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Harland, M.
Right arrow Articles by Bishop, J. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harland, M.
Right arrow Articles by Bishop, J. N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, Vol 6, 2061-2067, Copyright © 1997 by Oxford University Press

ARTICLES

Germline mutations of the CDKN2 gene in UK melanoma families

M Harland, R Meloni, N Gruis, E Pinney, S Brookes, NK Spurr, AM Frischauf, V Bataille, G Peters, J Cuzick, P Selby, DT Bishop and JN Bishop
ICRF Cancer Medicine Research Unit, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK.

Germline mutations in CDKN2 on chromosome 9p21, which codes for the cyclin D kinase inhibitor p16, and more rarely, mutations in the gene coding for CDK4, the protein to which p16 binds, underlie susceptibility in some melanoma families. We have sequenced all exons of CDKN2 and analysed the CDK4 gene for mutations in 27 UK families showing evidence of predisposition to melanoma. Five different germline mutations in CDKN2 were found in six families. Three of the mutations (Met53Ile, Arg24Pro and 23ins24) have been reported previously. We have identified two novel CDKN2 mutations (88delG and Ala118Thr) which are likely to be associated with the development of melanoma, because of their co-segregation with the disease and their likely functional effect on the CDKN2 protein. In binding assays the protein expressed from the previously described mutation, Met53Ile, did not bind to CDK4/CDK6, confirming its role as a causal mutation in the development of melanoma. Ala118Thr appeared to be functional in this assay. Arg24Pro appeared to bind to CDK6, but not to CDK4. No mutations were detected in exon 2 of CDK4, suggesting that causal mutations in this gene are uncommon. The penetrance of these mutant CDKN2 genes is not yet established, nor is the risk of non-melanoma cancer to gene carriers.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
D. E. Freedberg, S. H. Rigas, J. Russak, W. Gai, M. Kaplow, I. Osman, F. Turner, J. A. Randerson-Moor, A. Houghton, K. Busam, et al.
Frequent p16-Independent Inactivation of p14ARF in Human Melanoma
J Natl Cancer Inst, June 4, 2008; 100(11): 784 - 795.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Jones, M. Ruas, F. Gregory, S. Moulin, D. Delia, S. Manoukian, J. Rowe, S. Brookes, and G. Peters
A CDKN2A Mutation in Familial Melanoma that Abrogates Binding of p16INK4a to CDK4 but not CDK6
Cancer Res., October 1, 2007; 67(19): 9134 - 9141.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. S. Lindstrom, B. Yip, P. Lichtenstein, Y. Pawitan, and K. Czene
Etiology of Familial Aggregation in Melanoma and Squamous Cell Carcinoma of the Skin
Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1639 - 1643.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. N. Markovic, L. A. Erickson, R. D. Rao, R. R. McWilliams, L. A. Kottschade, E. T. Creagan, R. H. Weenig, J. L. Hand, M. R. Pittelkow, B. A. Pockaj, et al.
Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis
Mayo Clin. Proc., March 1, 2007; 82(3): 364 - 380.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Puig, J. Malvehy, C. Badenas, A. Ruiz, D. Jimenez, F. Cuellar, A. Azon, U. Gonzalez, T. Castel, A. Campoy, et al.
Role of the CDKN2A Locus in Patients With Multiple Primary Melanomas
J. Clin. Oncol., May 1, 2005; 23(13): 3043 - 3051.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Debniak, R. J. Scott, T. Huzarski, T. Byrski, A. Rozmiarek, B. Debniak, E. Zaluga, R. Maleszka, J. Kladny, B. Gorski, et al.
CDKN2A Common Variants and Their Association with Melanoma Risk: A Population-Based Study
Cancer Res., February 1, 2005; 65(3): 835 - 839.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
J. F. Parker, S. R. Florell, A. Alexander, J. A. DiSario, P. J. Shami, and S. A. Leachman
Pancreatic Carcinoma Surveillance in Patients With Familial Melanoma
Arch Dermatol, August 1, 2003; 139(8): 1019 - 1025.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Gump, D. Stokoe, and F. McCormick
Phosphorylation of p16INK4A Correlates with Cdk4 Association
J. Biol. Chem., February 21, 2003; 278(9): 6619 - 6622.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Rizos, E. Diefenbach, P. Badhwar, S. Woodruff, T. M. Becker, R. J. Rooney, and R. F. Kefford
Association of p14ARF with the p120E4F Transcriptional Repressor Enhances Cell Cycle Inhibition
J. Biol. Chem., February 7, 2003; 278(7): 4981 - 4989.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
T. J. Huot, J. Rowe, M. Harland, S. Drayton, S. Brookes, C. Gooptu, P. Purkis, M. Fried, V. Bataille, E. Hara, et al.
Biallelic Mutations in p16INK4a Confer Resistance to Ras- and Ets-Induced Senescence in Human Diploid Fibroblasts
Mol. Cell. Biol., December 1, 2002; 22(23): 8135 - 8143.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
M. Harland, S. Mistry, D. T. Bishop, and J. A. Newton Bishop
A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees
Hum. Mol. Genet., November 1, 2001; 10(23): 2679 - 2686.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. M. Becker, H. Rizos, R. F. Kefford, and G. J. Mann
Functional Impairment of Melanoma-associated p16INK4a Mutants in Melanoma Cells despite Retention of Cyclin-dependent Kinase 4 Binding
Clin. Cancer Res., October 1, 2001; 7(10): 3282 - 3288.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. A. van der Velden, J. A. W. Metzelaar-Blok, W. Bergman, H. Monique, H. Hurks, R. R. Frants, N. A. Gruis, and M. J. Jager
Promoter Hypermethylation: A Common Cause of Reduced p16INK4a Expression in Uveal Melanoma
Cancer Res., July 1, 2001; 61(13): 5303 - 5306.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
J. A. Randerson-Moor, M. Harland, S. Williams, D. Cuthbert-Heavens, E. Sheridan, J. Aveyard, K. Sibley, L. Whitaker, M. Knowles, J. Newton Bishop, et al.
A germline deletion of p14ARF but not CDKN2A in a melanoma-neural system tumour syndrome family
Hum. Mol. Genet., January 1, 2001; 10(1): 55 - 62.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
H. Tsao, X. Zhang, K. Kwitkiwski, D. M. Finkelstein, A. J. Sober, and F. G. Haluska
Low Prevalence of Germline CDKN2A and CDK4 Mutations in Patients With Early-Onset Melanoma
Arch Dermatol, September 1, 2000; 136(9): 1118 - 1122.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. Borg, T. Sandberg, K. Nilsson, O. Johannsson, M. Klinker, A. Masback, J. Westerdahl, H. Olsson, and C. Ingvar
High Frequency of Multiple Melanomas and Breast and Pancreas Carcinomas in CDKN2A Mutation-Positive Melanoma Families
J Natl Cancer Inst, August 2, 2000; 92(15): 1260 - 1266.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
V. Bataille, H. Snieder, A. J. MacGregor, P. Sasieni, and T. D. Spector
Genetics of Risk Factors for Melanoma: an Adult Twin Study of Nevi and Freckles
J Natl Cancer Inst, March 15, 2000; 92(6): 457 - 463.
[Abstract] [Full Text] [PDF]

Home page
 Genome ResHome page
P. A. van der Velden, L. A. Sandkuijl, W. Bergman, E. T.M. Hille, R. R. Frants, and N. A. Gruis
A Locus Linked to p16 Modifies Melanoma Risk in Dutch Familial Atypical Multiple Mole Melanoma (FAMMM) Syndrome Families
Genome Res., June 1, 1999; 9(6): 575 - 580.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Aitken, J. Welch, D. Duffy, A. Milligan, A. Green, N. Martin, and N. Hayward
CDKN2A Variants in a Population-Based Sample of Queensland Families With Melanoma
J Natl Cancer Inst, March 3, 1999; 91(5): 446 - 452.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
A. D. Burden, J. Newell, N. Andrew, G. Kavanagh, J. M. Connor, and R. M. MacKie
Genetic and Environmental Influences in the Development of Multiple Primary Melanoma
Arch Dermatol, March 1, 1999; 135(3): 261 - 265.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J.-C. Bystryn, T.H. Hughes-Davies, N. J. Lassam, D. Hogg, and J. McLaughlin
CDKN2A Mutations in Multiple Primary Melanomas
N. Engl. J. Med., July 30, 1998; 339(5): 347 - 348.
[Full Text]

Home page
 NEJMHome page
R. C. Wachsmuth, M. Harland, and J. A. N. Bishop
The Atypical-Mole Syndrome and Predisposition to Melanoma
N. Engl. J. Med., July 30, 1998; 339(5): 348 - 349.
[Full Text]

Home page
 J. Biol. Chem.Home page
H. Rizos, A. P. Darmanian, E. A. Holland, G. J. Mann, and R. F. Kefford
Mutations in the INK4a/ARF Melanoma Susceptibility Locus Functionally Impair p14ARF
J. Biol. Chem., October 26, 2001; 276(44): 41424 - 41434.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.